Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC

被引：0
作者：
Rothschild, S. I. [1 ]
Leger, P. [2 ]
Castellanos, E. L. [2 ]
Pillai, R. N. [3 ]
York, S. J. [2 ]
Horn, L. [2 ]
机构：
[1] Univ Spital Basel, Dept Internal Med, Med Oncol, Basel, Switzerland
[2] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
91PD-PR
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Progress on biphenyl derivatives as PD-1/PD-L1 inhibitors
    Wang, Shurong
    Wang, Yuli
    Yan, Hong
    MEDICINAL CHEMISTRY RESEARCH, 2023, 32 (10) : 2089 - 2115
  • [42] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hidetoshi Hayashi
    Kazuhiko Nakagawa
    International Journal of Clinical Oncology, 2020, 25 : 818 - 830
  • [43] Efficiency of PD-1 and PD-L1 Inhibitors in Malignant Therapy
    Gappa, Birgit
    Kobold, Sebastian
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (01) : 7 - 8
  • [44] Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
    Laurence P. Diggs
    Eddy C. Hsueh
    Biomarker Research, 5
  • [45] Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer
    Yao, W.
    Zhao, X.
    Gong, Y.
    Zhang, M.
    Zhang, L.
    Wu, Q.
    Wu, L.
    Fan, Z.
    Yan, X.
    Jiao, S.
    ESMO OPEN, 2021, 6 (02)
  • [46] Chemotherapy thorn PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC
    Hendriks, Lizza E. L.
    Remon, Jordi
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 499 - 502
  • [47] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [48] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
  • [49] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
    Guo, Jiazheng
    Yu, Fengyi
    Zhang, Kuojun
    Jiang, Sheng
    Zhang, Xiangyu
    Wang, Tianyu
    RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108
  • [50] Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
    Diggs, Laurence P.
    Hsueh, Eddy C.
    BIOMARKER RESEARCH, 2017, 5
12345